Any company that manufactures, imports, distributes, or sells medical devices in Malaysia operates within a regulatory framework built around one central requirement: no medical device may be imported, marketed, or used in Malaysia unless it is registered with the Medical Device Authority (“MDA”). For manufacturers, distributors, and healthcare providers, understanding this framework — and the 2026 changes reshaping it — is essential to avoiding compliance gaps, product seizures, and liability exposure.
Malaysia’s medical device regime affects the full product lifecycle — from initial classification and registration through to post-market surveillance, adverse event reporting, and recalls. Getting the framework right from the outset materially reduces the risk of regulatory delay and downstream liability.
What Is Medical Device Regulation in Malaysia?
Medical device regulation in Malaysia is the statutory framework, established under Act 737, that governs how medical devices are classified, registered, imported, distributed, and monitored throughout their lifecycle. Enforcement sits with the MDA, a body operating under the Ministry of Health.
A key feature of Act 737 is that it regulates the entire supply chain — manufacturers, importers, distributors, and Authorised Representatives alike — rather than only the point of initial approval. Registration is submitted electronically through the MDA’s Medical Device Centralised Online Application System (“MeDC@St”), though this can only be done by a licensed local entity.
Any entity wishing to import, export, manufacture, or distribute a registered device in Malaysia must also hold a valid establishment licence — a separate MDA-issued operating licence, distinct from device registration itself.
Risk-Based Classification: Class A to D
Malaysia’s classification system is closely aligned with the ASEAN Medical Device Directive, sorting devices into four risk tiers:
| Class | Risk Level | Typical Examples |
|---|---|---|
| Class A | Low risk | Surgical retractors, tongue depressors |
| Class B | Low-to-moderate risk | Hypodermic needles, suction equipment |
| Class C | Moderate-to-high risk | More invasive or higher-risk diagnostic/therapeutic devices |
| Class D | Highest risk | Devices with significant patient impact (e.g. certain implantables, high-risk IVDs) |
The classification assigned to a device dictates both the complexity of the technical documentation required and whether a CAB review is necessary before submission to the MDA. Class A medical devices can generally be submitted directly to the MDA without prior CAB assessment. However, extra evidence may still be needed if the device is supplied sterile or has a measuring function. Class B, C and D devices must undergo CAB conformity assessment before registration. Getting the classification right from the start can help avoid unnecessary delays, extra queries, or rejection during the registration process.
The Local Authorised Representative Requirement
For foreign manufacturers, one requirement in particular tends to catch companies off guard: registration cannot be submitted directly. A manufacturer based outside Malaysia must appoint a Local Authorised Representative before its products can be registered or legally sold in the country.
The LAR acts as the formal liaison with the MDA and takes on regulatory accountability for the manufacturer’s products within Malaysia — managing submissions, maintaining device records, coordinating renewals, reporting adverse events, and handling recalls or corrective actions where necessary.
Key consideration Because the LAR effectively controls the device’s regulatory standing in-market, manufacturers are generally advised to select their Authorised Representative independently of distribution arrangements, since a distributor’s commercial incentives do not always align with ongoing regulatory obligations.
Where a device is already approved in a recognised reference market — the United States, European Union, Australia, Japan, or Canada — Malaysia permits an abridged registration pathway that leverages the existing approval, which can meaningfully shorten review timelines compared to a full first-time submission.
2026 Regulatory Updates: What’s Changed
Malaysia’s medical device framework has seen active development through 2025 and into 2026, with several changes carrying direct implications for manufacturers, distributors, and clinics.
Medical Device (Designated Medical Devices) Order 2026
The most significant recent development is the Medical Device (Designated Medical Devices) Order 2026, gazetted in early 2026 and taking effect 1 June 2026. Made under Section 26 of Act 737, the Order empowers the Minister of Health to designate specific devices as regulated medical devices where their risk profile, tissue interaction, or invasive nature warrants it.
The Order specifically brings certain aesthetic and cosmetic technologies — including defined categories of medical lasers (identified by wavelength), High-Intensity Focused Ultrasound (“HIFU”) devices, and liposuction systems — formally within the scope of MDA regulation. These devices, previously treated in some cases as general beauty equipment, are now subject to the registration, safety, and performance requirements applicable to regulated medical devices. Their operation is restricted to persons holding the required designated medical device permit under Section 27 of Act 737, ensuring that such devices are used only by persons recognised as appropriately qualified and competent by the relevant authorities.
Key consideration For manufacturers, importers, distributors, and aesthetic service providers, the practical implications are immediate: products falling within the designated categories should be reviewed against the Order’s schedule, compliance documentation prepared ahead of the 1 June 2026 deadline, and regulatory pathways implemented early to avoid disruption to market access.
Broader Post-Market and Quality System Developments
Alongside the Designated Medical Devices Order, MDA guidance has continued to evolve. Malaysia’s participation in the Medical Device Single Audit Program allows manufacturers holding recognised quality system certification to rely on it as evidence for MDA registration, reducing the need for a separate quality system audit.
Updated MDA guidance has also standardised post-market surveillance documentation expectations, giving manufacturers clearer review timelines to plan around.
Taken together, these developments point toward a regulatory environment that is becoming more structured and more transparent — a trend consistent with Malaysia’s broader efforts to align with international medical device regulatory practice.
Medical Device Compliance Malaysia: Ongoing Obligations
Registration is not a one-time event. Ongoing medical device compliance obligations in Malaysia include:
- Post-market surveillance — monitoring device performance in the field and reporting adverse events to the MDA;
- Labelling compliance — device labels and Instructions for Use must meet MDA requirements, generally in English, with Bahasa Malaysia required for home-use devices, and must not imply endorsement by the Ministry of Health or MDA;
- Registration renewal — maintaining current registration status and notifying the MDA of significant device changes; and
- Recall and corrective action management — coordinating any field corrective action or product recall through the LAR.
Key consideration An authorised officer may investigate potential violations of Act 737, and a manufacturer or responsible party found in breach may face fines, product seizure, or imprisonment, alongside licence suspension. Given the seriousness of these consequences, compliance is best treated as a continuous obligation rather than a milestone completed at first registration.
Medical Device Manufacturer Liability: Where Regulation Meets Litigation
Regulatory compliance under Act 737 and product liability exposure are closely linked but distinct. A device that is properly registered and compliant with MDA requirements can still give rise to medical device manufacturer liability claims where a patient is harmed by a defective design, manufacturing fault, or inadequate warning.
Conversely, non-compliance with registration or labelling requirements can itself become evidence in a subsequent liability claim, or trigger regulatory enforcement independent of any civil action.
For manufacturers and distributors, this means regulatory strategy and litigation risk management should be considered together — from the pre-market classification and technical documentation stage through to post-market surveillance and, where necessary, product recalls and crisis management.
Disputes involving medical devices also frequently intersect with the position of the healthcare professionals or institutions that used the device, making advice that spans both the manufacturer’s and the practitioner’s exposure especially valuable. Given the increasing regulatory scrutiny reflected in the 2026 updates, this integrated approach is becoming more, not less, important.
Frequently Asked Questions
Does a properly MDA-registered device eliminate liability risk?
No. MDA registration confirms regulatory compliance but does not, by itself, protect a manufacturer from product liability claims arising from defective design, manufacture, or inadequate instructions for use.
Do the 2026 aesthetic device changes apply to devices already in clinical use?
The Designated Medical Devices Order 2026 applies from 1 June 2026, and affected manufacturers, importers, distributors, and service providers should review existing product lines against the Order’s designated categories well ahead of that date rather than waiting for enforcement.
Can a foreign manufacturer register a medical device without a Malaysian entity?
Yes, provided the manufacturer appoints a Local Authorised Representative to manage the registration and act as the regulatory liaison with the MDA — a Malaysian corporate presence is not itself required.
Conclusion
Medical device regulation in Malaysia continues to evolve, and the 2026 updates — most notably the Designated Medical Devices Order bringing aesthetic technologies within Act 737’s scope — are a reminder that the regulatory perimeter is actively expanding rather than static.
For manufacturers, distributors, and healthcare providers, staying compliant requires monitoring classification changes, maintaining rigorous post-market documentation, and understanding how regulatory compliance and product liability exposure interact.
Shearn Delamore & Co.’s Medico-Legal practice advises on product liability issues pertaining to medical devices and equipment, and represents clients in related litigation and regulatory proceedings.
If you would like to discuss how the 2026 regulatory updates affect your compliance or liability position, please contact our team.
